Connecticut § 3-123m - Drug Discount Card Program. Study re feasibility of centralizing state-wide contracts to consolidate purchasing of prescription and physician-administered drugs by state agencies.

§ 3-123m. Drug Discount Card Program. Study re feasibility of centralizing state-wide contracts to consolidate purchasing of prescription and physician-administered drugs by state agencies.

Sec. 3-123m. Drug Discount Card Program. Study re feasibility of centralizing state-wide contracts to consolidate purchasing of prescription and physician-administered drugs by state agencies. (a) The Comptroller shall establish the Drug Discount Card Program to be made available to all residents of this state. To further the purpose of such program, the Comptroller may cooperate with other states and territories of the United States, or regional consortia to pool prescription drug purchasing power to (1) lower prescription drug costs, (2) negotiate discounts with prescription drug manufacturers, (3) centralize the purchasing of prescription drugs, and (4) establish volume discount contracting. As used in this subsection, “volume discount contracting” means a negotiated purchase of a prescription drug in a large quantity for a decreased cost.

(b) The Comptroller shall study the feasibility of centralizing state-wide contracts to consolidate the purchasing of prescription and physician-administered drugs by state agencies, state hospitals, state-operated local mental health authorities and other public entities, as necessary. The study shall include an evaluation of (1) the potential cost savings, administrative feasibility and other benefits and risks of centralizing and consolidating contracts, and (2) any additional staff and resources required by the Comptroller to centrally procure and administer such contracts. Not later than November 1, 2023, each state agency, state hospital, state-operated local mental health authority and other public entity, as necessary, that procures prescription or physician-administered drugs shall provide information regarding the types, amount and cost of such drugs to the Comptroller, in a form and manner prescribed by the Comptroller. Not later than February 1, 2024, the Comptroller shall submit a report regarding the findings of such study to the Governor and, in accordance with the provisions of section 11-4a, to the General Assembly.

(P.A. 23-171, S. 1.)

Secs. 3-123n to 3-123z. Reserved for future use.

PART II

CONNECTICUT HOME CARE TRUST FUND